The same United States House of Representatives that voted to let Veterans Administration doctors help vets access medical cannabis also voted, nearly simultaneously, to block the federal rescheduling process that would make such access legally coherent. That is not mixed signals; it is a fractured federal posture. For the roughly 9 million veterans enrolled in VA healthcare, it lands with consequences that are anything but abstract.
- The contradiction: The U.S. House simultaneously advanced an amendment to grant veterans medical cannabis access while a committee voted (Section 591) to defund the historic Schedule III rescheduling process.
- The cost to veterans: Under current VHA Directive 1315, VA doctors cannot sign state enrollment forms. This restriction forces veterans to spend $150 to $500 out-of-pocket for private doctors just to access legal medicine.
- Executive vs. legislative: The House committee’s defunding vote directly pushes back against the executive branch’s recent momentum, following Acting AG Todd Blanche’s April order moving state-licensed medical cannabis to Schedule III.
- What’s next: The broader federal rescheduling process hinges entirely on a DEA administrative hearing scheduled for June 29 — contingent on whether the budget defunding rider survives conference committee negotiations.
- The bottom line: Congress isn’t building a unified cannabis policy; it is actively funding a contradiction, leaving 9 million veterans and industry operators caught in the regulatory crossfire.
On May 14, the House passed an amendment to the Fiscal Year 2027 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act by voice vote. The amendment, co-sponsored by Representatives Brian Mast (R-FL), Dave Joyce (R-OH), and Dina Titus (D-NV), would, if enacted, prevent the VA from enforcing the provisions of Veterans Health Administration Directive 1315 that bar providers from helping veterans access state-approved medical cannabis programs. If signed into law, VA doctors will be able to sign the required forms.
One day earlier, the House Appropriations Committee passed Section 591 of the FY2027 Commerce, Justice, Science, and Related Agencies Bill, 32–28. The text is spare but potent: “None of the funds appropriated under this Act or otherwise made available by this Act may be used [by the Department of Justice] to reschedule marijuana […] or to remove marijuana from the schedules established under section 202 of the Controlled Substances Act.”
It’s a classic example of “what Congress giveth with one hand, Congress taketh away with the other.”
Understanding VHA Directive 1315 and the cost of care
To understand why the legislative simultaneity matters, one must understand exactly what Directive 1315 does — and what it costs veterans.
Under Directive 1315, revised July 2023, VA healthcare providers are “prohibited from recommending, making referrals to, completing forms or registering Veterans for participation in a State-approved marijuana program.” A VA doctor can ask a veteran about cannabis use. They can document it in the veteran’s medical file. They can discuss drug interactions. What they cannot do is sign the form a state’s medical program requires for enrollment. That requires a private physician.
Private cannabis evaluations typically cost $75 to $300, depending on state and visit type. Add state registration fees — as much as $150 in some states — and a new veteran patient may spend $150 to $500 just to legally access the plant. The VA covers prescription medications for enrolled veterans, but cannabis, by directive and federal law, is explicitly excluded. For veterans on fixed incomes, that financial wall is not an inconvenience. It is the gap between treatment and continued suffering.
The numbers give scale to those stakes. A March 2025 study found 40 percent of veterans with chronic pain reported using cannabis to manage symptoms. Pain and mobility were cited as the primary reason for cannabis use by 81 percent of respondents. Another 62 percent cited sleep, and 43 percent cited PTSD or anxiety. A May 2025 Veterans Health Administration cohort study found more than one in 10 veterans aged 65 to 84 had used cannabis in the past 30 days. More than 20 percent of veterans aged 18 to 44 report cannabis use. These are not recreational users gaming a policy gap. They are people who came home from recent foreign actions carrying injuries the VA has struggled to treat, paying out of pocket for relief their own providers cannot officially acknowledge.
The Mast-Joyce-Titus amendment: what it changes (and what it doesn’t)
The Mast-Joyce-Titus amendment would bar the VA from enforcing the form-completion prohibition of Directive 1315 in states where medical cannabis is legal. VA doctors could complete enrollment paperwork. Veterans could enter state programs through their own care team.
What it would not change: The VA still would not pay for approved medical cannabis products. Veterans would still pay out of pocket for the plant. Cannabis would remain prohibited on VA property.
Critically, since this is an appropriations rider, it must survive Senate consideration and conference committee negotiations. A similar measure cleared both chambers in mid-2025, then was stripped in conference before the FY2026 budget bill was signed into law. The version that became law in November 2025 omitted veterans’ medical cannabis access. The current amendment has the shape of progress. It does not yet have the weight of law.
Section 591: the legislative effort to block Schedule III
Section 591 is, in some ways, the stranger story, because the committee’s action directly contradicts the Trump administration’s posture on rescheduling.
On December 18, 2025, President Trump signed an executive order directing the Attorney General to expedite rescheduling from Schedule I to Schedule III. On April 23, 2026, Acting Attorney General Todd Blanche followed through when he signed an order placing marijuana products approved by the Food and Drug Administration as well as state-licensed medical marijuana products on Schedule III. At the same time, the Drug Enforcement Administration set June 29, 2026, as the start date for an administrative hearing to determine whether cannabis should move to Schedule III more broadly. Adult-use cannabis remains on Schedule I.
The executive branch was moving forward on reform. Then a Republican-led committee voted to stop progress.
Arguments marshaled for Section 591 leaned on public health concerns: high-potency products, links to teen psychosis, impaired driving, mixed messages to young people. There were procedural objections as well: The FDA has not formally found cannabis safe and effective, and the rescheduling order bypasses the randomized controlled trial standard DEA historically has required.
What Section 591 does not address is what passage of the bill as-is would do to the June 29 hearing. That administrative proceeding — the formal process that would determine the full scope of rescheduling — could be defunded before it begins if the provision passes into law. The Veterans of Foreign Wars called Trump’s December executive order a step that “prioritizes science over stigma.” The Iraq and Afghanistan Veterans of America applauded the therapeutic recognition while noting that rescheduling alone doesn’t solve access, equity, or protection for veterans. Both organizations were watching the same reform take shape. Both are now watching a committee try to shut it down.
Market impact: what the cannabis policy split means for operators and investors
For operators, the immediate read is familiar: The regulatory environment remains contested. Blanche’s April order already has begun unwinding some 280E tax exposure for state-licensed medical operators. Section 591, if it becomes law, doesn’t reverse that order, but it does foreclose expansion of those benefits through the hearing process. Investors modeling full Schedule III economics should treat the committee vote as a material risk factor, not a procedural footnote.
For advocates, the pattern should be clarifying. The VA amendment passing by voice vote reflects genuine bipartisan consensus on the narrow question of whether VA doctors should be allowed to complete enrollment forms. What is also real is the same measure has been stripped in conference before, and the Senate has yet to act. Progress in one chamber is not the same as enacted law, and voice-voting for the VA amendment cost nothing. Nobody has to defend a pro-veterans vote in a tough primary election. Stripping the amendment in conference, where the votes are quiet and accountability is diffuse, costs nothing either.
For veterans — the roughly 9 million in VA healthcare who are living in the gap between what is legal and what they can access — the calculus is unchanged today. Their doctors still cannot complete a form. The hearing that could change the federal framework is scheduled for June 29, contingent on a funding provision that may or may not survive.
The next critical steps for federal cannabis policy
The legal conflict between Directive 1315 and the Blanche order
The directive’s prohibition on provider participation in state cannabis programs rests on a specific legal foundation: cannabis’s Schedule I status under the Controlled Substances Act — no accepted medical use, highest abuse potential, the full framework. The Blanche order changed that foundation for state-licensed medical cannabis. Schedule III carries a different legal character entirely. The VA has not acknowledged this publicly, but the implication is uncomfortable for the department: It is now operating under a clinical prohibition whose statutory predicate the executive branch has formally abandoned. That’s not a political argument. It’s a structural one. Directive 1315 is an internal administrative document, not a statute. The VA Secretary can revise or rescind it without an act of Congress. The directive was last updated in July 2023, demonstrating the language moves when the department decides to move it. The Trump administration ordered rescheduling. If the VA declines to revisit 1315 in response, it will be the executive branch contradicting itself on its own policy.
A counterargument exists and deserves acknowledgment: Cannabis still lacks FDA approval for any specific clinical indication, which gives the VA independent grounds to maintain the directive’s restrictions regardless of schedule. That argument is weaker post-Blanche, but it is available to the department and likely to be invoked. What advocates should be pressing for — and what reporters should be asking — is whether the VA Secretary has been formally asked to review Directive 1315 in light of the rescheduling order, and what the answer was. The absence of that exchange on the public record is itself a signal.
The Senate’s role in surviving the conference committee
Whether the VA amendment survives into an enrolled bill is the near-term question, and the answer lies with the Senate and subsequent conference committee. A Senate companion bill would strengthen the Mast-Joyce-Titus amendment’s position substantially; its absence is a vulnerability.
The fate of the June 29 rescheduling hearing
If Section 591 does not survive into final law, the broader rescheduling process will proceed. If the section lands in a signed spending bill, the hearing’s legal and financial footing will be contested. The distance between those two outcomes is measured in conference committee votes.
Congress has not built a cannabis policy. It has built a contradiction and applied it to the people who can least afford to wait for the institution to sort itself out.
